146 262

Cited 62 times in

Bevacizumab application delays epithelial healing in rabbit cornea

Authors
 Tae-im Kim  ;  Jae Lim Chung  ;  Jin Pyo Hong  ;  Kyung Min  ;  Kyoung Yul Seo  ;  Eung Kweon Kim 
Citation
 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, Vol.50(10) : 4653-4659, 2009 
Journal Title
 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 
ISSN
 0146-0404 
Issue Date
2009
MeSH
Angiogenesis Inhibitors/pharmacology* ; Animals ; Antibodies, Monoclonal/pharmacology* ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Collagen Type I/genetics ; Collagen Type I/metabolism ; Collagen Type IV/genetics ; Collagen Type IV/metabolism ; Debridement ; Disease Models, Animal* ; Epithelium, Corneal/drug effects* ; Epithelium, Corneal/injuries ; Epithelium, Corneal/metabolism ; Fibroblasts/drug effects ; Fibroblasts/metabolism ; Integrin alpha Chains/genetics ; Integrin alpha Chains/metabolism ; Integrin beta Chains/genetics ; Integrin beta Chains/metabolism ; Ki-67 Antigen/metabolism ; RNA, Messenger/metabolism ; Rabbits ; Reverse Transcriptase Polymerase Chain Reaction ; Time Factors ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Wound Healing/drug effects*
Abstract
PURPOSE: Vascular endothelial growth factor (VEGF) is essential for neovascularization, but the use of anti-VEGF therapies to inhibit neovascularization may influence epithelial wound healing. Here, the effects of bevacizumab on corneal epithelial wound healing time in rabbit models, cell proliferation, and expression of integrins in human corneal epithelial and fibroblast cells were evaluated. METHODS: To compare epithelial wound healing times, epithelial defect sizes were measured after application of bevacizumab topical eye drops at 0, 0.5, 1.0, 1.5, 2.5, or 5 mg/mL, twice daily, to mechanically debrided epithelia of rabbit corneas. The cellular covering of wounded areas and expression of Ki67 were assessed after scrape injuries in cultures of human corneal epithelial and fibroblast cells. Expression of cell surface integrins and collagens was measured using plates coated with mouse monoclonal antibodies against human adhesion molecules, and relevant mRNA levels were assessed by reverse-transcription-polymerase chain reaction (RT-PCR). RESULTS: The application of bevacizumab topical eye drops at 1.0, 1.5, 2.5, or 5 mg/mL delayed rabbit corneal epithelial healing. Cell cultures growing under high concentrations of bevacizumab showed delay in the proliferation of corneal epithelial and fibroblast cells. Surface expression of mRNA encoding integrins and collagens were decreased by 1.5 mg/mL of bevacizumab. CONCLUSIONS: Bevacizumab delayed corneal epithelial wound healing and inhibited integrin expression. When bevacizumab is used to reduce the development of new corneal vessels, slight delays in epithelial wound healing are possible and cellular proliferation is to be expected
Files in This Item:
T200902798.pdf Download
DOI
10.1167/iovs.08-2805
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Eung Kweon(김응권) ORCID logo https://orcid.org/0000-0002-1453-8042
Kim, Tae Im(김태임) ORCID logo https://orcid.org/0000-0001-6414-3842
Seo, Kyuong Yul(서경률) ORCID logo https://orcid.org/0000-0002-9855-1980
Chung, Jae Lim(정재림)
Hong, Jin Pyo(홍진표)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/104382
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse